Please login to the form below

Not currently logged in
Email:
Password:

thalidomide

This page shows the latest thalidomide news and features for those working in and with pharma, biotech and healthcare.

Celgene reaches $9bn agreement to buy Juno

Celgene reaches $9bn agreement to buy Juno

Celgene is already a big player in blood cancers and haematology with Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide), and buying Juno keeps it in the running for a new generation

Latest news

More from news
Approximately 3 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Does safety sell medicines? Does safety sell medicines?

    Who would have thought 50 years ago that thalidomide would be back on the UK market helping patients with life-threatening multiple myeloma - possible due to a risk management programme centered

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics